Dry Age Macular Degeneration (Dry AMD) Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, about 58+ key pharma and biotech companies are working on 64+ pipeline drugs in the Dry Age Macular Degeneration therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Dry Age Macular Degeneration (Dry AMD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Dry Age Macular Degeneration Market.

The Dry Age Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Dry Age Macular Degeneration (Dry AMD) Pipeline Analysis
The report provides insights into:

– The report provides detailed insights about emerging therapies for the treatment of Dry Age Macular Degeneration and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Age Macular Degeneration Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Dry Age Macular Degeneration market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates

Route of Administration
Dry Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
– Intra-articular
– Intraocular
– Intrathecal
– Intravenous
– Ophthalmic
– Oral
– Parenteral
– Subcutaneous
– Topical
– Transdermal

Molecule Type
Products have been categorized under various Molecule types, such as
– Oligonucleotide
– Peptide
– Small molecule

Dry Age Macular Degeneration (Dry AMD) Therapeutics Landscape

There are approx. 55+ key companies developing therapies for Dry Age-related Macular Degeneration. Currently, Alkeus Pharmaceuticals is leading the therapeutics market with its Dry Age-related Macular Degeneration drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Dry Age Macular Degeneration (Dry AMD) Therapeutics Market include:

– 4D Molecular Therapeutics
– Aevitas Therapeutics
– Alexion AstraZeneca Rare Disease
– Amarna Therapeutics
– Apellis Pharmaceuticals
– Aviceda Therapeutics
– Belite Bio
– Cognition Therapeutics
– Galimedix Therapeutics
– InflammX Therapeutics
– Isarna Therapeutics
– Katairo
– Lineage Cell Therapeutics
– Molecular Partners
– NGM Biopharmaceuticals
– Regenerative Patch Technologies
– Stealth BioTherapeutics
And many others

Dry Age Macular Degeneration (Dry AMD) Therapies covered in the report include:

– ALK-001: Alkeus Pharmaceuticals
– Elamipretide: Stealth BioTherapeutics
– CPCB-RPE1: Regenerative Patch Technologies
– AAV.sFH: Aevitas Therapeutics
And many more

Explore More About the Emerging Drugs and Key Companies: Dry Age Macular Degeneration Pipeline Development Activities

Table of Content (TOC)

1. Report Introduction
2. Executive Summary
3. Dry Age Macular Degeneration Current Treatment Patterns
4. Dry Age Macular Degeneration – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Dry Age Macular Degeneration Late-Stage Products (Phase-III)
7. Dry Age Macular Degeneration Mid-Stage Products (Phase-II)
8. Dry Age Macular Degeneration Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Dry Age Macular Degeneration Discontinued Products
13. Dry Age Macular Degeneration Product Profiles
14. Key Companies in the Dry Age Macular Degeneration Market
15. Key Products in the Dry Age Macular Degeneration Therapeutics Segment
16. Dormant and Discontinued Products
17. Dry Age Macular Degeneration Unmet Needs
18. Dry Age Macular Degeneration Future Perspectives
19. Dry Age Macular Degeneration Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Dry Age Macular Degeneration Therapeutic Outlook

Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Solutions

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.